Short Interest in Kenvue Inc. (NYSE:KVUE) Decreases By 12.9%

Kenvue Inc. (NYSE:KVUE) saw a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 58,159,600 shares, a drop of 12.9% from the February 26th total of 66,801,459 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average daily trading volume, of 29,600,865 shares, the short-interest ratio is currently 2.0 days.

Kenvue Stock Down 1.7%

Shares of Kenvue stock opened at $17.22 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. Kenvue has a 12 month low of $14.02 and a 12 month high of $25.17. The business has a fifty day simple moving average of $18.01 and a 200 day simple moving average of $17.11. The stock has a market cap of $33.00 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 3.98 and a beta of 0.51.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. During the same quarter in the prior year, the firm posted $0.26 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Research analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.8%. Kenvue’s dividend payout ratio is 107.79%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of recent research reports. Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Friday, March 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Citigroup boosted their price objective on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. UBS Group upped their target price on shares of Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Finally, Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. J.W. Cole Advisors Inc. increased its stake in Kenvue by 3.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock valued at $324,000 after purchasing an additional 574 shares in the last quarter. Physician Wealth Advisors Inc. raised its holdings in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the period. Mill Creek Capital Advisors LLC boosted its position in shares of Kenvue by 0.6% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after purchasing an additional 701 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management grew its holdings in shares of Kenvue by 0.3% in the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock valued at $4,048,000 after buying an additional 712 shares during the period. Finally, Versor Investments LP grew its holdings in shares of Kenvue by 2.8% in the 3rd quarter. Versor Investments LP now owns 26,016 shares of the company’s stock valued at $422,000 after buying an additional 716 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.